Chemotherapy-Induced Peripheral Neuropathy
Conditions
Interventions
Guasha Therapy Group:Guasha Therapy
Control Group:Oral Mecobalamin Tablets Therapy
Sponsors
The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Patients with malignant tumors diagnosed by pathology or cytology (regardless of cancer type); (2) Patients who receive chemotherapy with neurotoxic drugs such as platinum and taxanes and meet the clinical diagnostic criteria for CIPN; (3) Patients with grade 2 (including grade 2) or above peripheral neurotoxicity assessed according to the NCI - CTCAE (v5.0) peripheral neurotoxicity grading criteria; (4) Aged 18 - 80 years, regardless of gender; (5) KPS score = 60; (6) No other diseases or conditions such as diabetes or neurological diseases that can cause peripheral neuropathy and similar symptoms in the past; (7) Voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with peripheral neuropathy caused by other reasons; (2) Patients with skin damage, ulcers, or scars at the acupuncture site; (3) Patients with severe bleeding tendency, hemorrhagic diseases, or severe coagulation dysfunction; (4) Patients with insufficiency of important organ functions such as heart, liver, and kidney, or suffering from mental diseases, who are assessed as unable to tolerate the intervention measures of this study; (5) Pregnant, lactating patients, patients with potential pregnancy, or those planning to become pregnant; (6) Patients who have participated in or are currently participating in other clinical trials within the past 3 months; (7) Patients who are deemed ineligible for the study by the researchers based on combined treatment and medical outcomes, or for other reasons; (8) Patients who, as assessed by the researchers, may be unable to complete the study or comply with the protocol requirements due to management issues (such as poor compliance, difficulty in follow-up) or other uncontrollable factors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Effective Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Karnofsky Performance Status Scale;European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Chemotherapy - Induced Peripheral Neuropathy 20 Scale;European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 version 3.0 Scale;Self-Rating Depression Scale;Self-Rating Anxiety Scale;Numerical Rating Scale;Peripheral Blood Lymphocyte Subsets Test Results; | — |
Countries
China
Contacts
Public ContactFanming Kong
Tianjin First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Outcome results
None listed